Nanoparticle-encapsulated retinoic acid for the modulation of bone marrow hematopoietic stem cell niche.

ABSTRACT: More effective approaches are needed in the treatment of blood cancers, in particular acute myeloid leukemia (AML), that are able to eliminate resistant leukemia stem cells (LSCs) at the bone marrow (BM), after a chemotherapy session, and then enhance hematopoietic stem cell (HSC) engraftment for the re-establishment of the HSC compartment. Here, we investigate whether light-activatable nanoparticles (NPs) encapsulating all-trans-retinoic acid (RA⁺NPs) could solve both problems. Our in vitro results show that mouse AML cells transfected with RA⁺NPs differentiate towards antitumoral M1 macrophages through RIG.1 and OASL gene expression. Our in vivo results further show that mouse AML cells transfected with RA⁺NPs home at the BM after transplant

SUBMITTER: Quartin E 

PROVIDER: S-EPMC10809008 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature